A prospective randomized trial was performed to detect technical and clinical differences of 7F compared to 8F guiding catheters (GC) used in elective coronary angioplasty (PTCA). One hundred and fifteen patients undergoing elective PTCA with standard balloon dilatation catheters were randomized to 7F (55 pts) or 8F (58 pts) guiding catheters. The endpoints were primarily coronary artery and peripheral vascular complications; and secondarily, technical details and quantitative and qualitative angiographic quality. There was no difference between 7F or 8F GC for development of coronary or peripheral vascular complications. With 7F GC there was less blood loss (Hct, 3.5 +/- 3.4% vs. 6.5 +/- 9.6%, P = .033), and less contrast medium (160 +/- 88 mL vs. 200 +/- 119 mL, P = .049) used. Angiographic quality was similar, although visualization of lesions in the left anterior descending coronary artery in the left anterior oblique projection was improved with the 8F GC. There is no advantage of 7F GC for the prevention of coronary or peripheral vascular complications, although there was less blood loss and contrast medium used with the 7F systems.
This report presents a case in which an angioplasty balloon catheter became entrapped within the lumen of a coronary artery after rupture during percutaneous transluminal coronary angioplasty (PTCA). Prior to this report, balloon rupture had been considered a relatively benign occurrence. However, this case demonstrates that balloon rupture may lead to serious complications.
The acute effects of rapid ventricular pacing and sustained ventricular tachycardia on left ventricular function were examined in patients with recurrent sustained ventricular tachycardia. Programmed electrical stimulation and left ventricular hemodynamic measurements were performed in 20 patients (19 men and 1 woman), with an age range of 49 to 79 years (mean 63 +/- 9). Indexes of left ventricular function that were analyzed included left ventricular peak systolic pressure, end-diastolic pressure, first derivative of peak left ventricular pressure (dP/dt) and negative left ventricular dP/dt. Measurements were obtained during sinus rhythm, after paced premature ventricular depolarizations, during rapid ventricular pacing (cycle lengths 600 to 250 ms) and immediately after induction of sustained ventricular tachycardia. Mean left ventricular peak systolic blood pressure was 123 +/- 19 mm Hg during sinus rhythm, decreased to 77 +/- 23 mm Hg (p less than 0.05) at the induction of ventricular tachycardia and remained decreased during arrhythmia (p less than 0.01). Mean left ventricular end-diastolic pressure was 22 +/- 5 mm Hg during sinus rhythm, did not change after arrhythmia induction (22 +/- 9 mm Hg, p greater than 0.2) and remained unchanged during sustained ventricular tachycardia (p greater than 0.2). Mean peak left ventricular dP/dt was 1,400 +/- 620 mm Hg/s in sinus rhythm, decreased to 810 +/- 580 mm Hg/s (p less than 0.05) at ventricular tachycardia induction and remained decreased during sustained ventricular tachycardia (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
The clinical efficacy and safety of transvenous cardioversion for termination of sustained ventricular tachycardia (VT) were examined by a prospective randomized study design in 22 patients (19 men, three women; mean age 64 ± 9 years) with organic heart disease and sustained VT. Patients were randomly assigned to undergo an incremental low-energy protocol from 0.03 to 2.2 J (group A, 11 patients) or an incremental high-energy protocol from 0.5 to 10.0 J (group B, 11 patients). Transvenous cardioversion was performed during electrophysiologic studies in the control (drug-free) state and during serial antiarrhythmic drug testing in all patients. Both groups were comparable for demographic, disease and functional status, and electrophysiologic parameters. A total of 77 episodes of VT (group A, 45; group B, 32) were analyzed. The overall efficacy of transvenous cardioversion for termination of VT was 62% (group A 56% vs group B 72%; p < .01). Antiarrhythmic drug therapy did not significantly enhance efficacy of transvenous cardioversion (control 59% vs drug 65%; p > .2).Stepwise discriminant analysis correlated successful transvenous cardioversion with longer VT cycle length (p < .0005), higher energy (p < .025), lower energy waveform tilt (p < .025), shorter time to initial cardioversion attempt (p < .025), and shorter QRS duration in sinus rhythm (p < .05). Acceleration of VT was frequent (8% incidence per delivered shock). Thirty-one percent of all incremental shock protocols were terminated because of this complication. After cardioversion, transient arrhythmias were common (bradyarrhythmias 23%, supraventricular tachyarrhythmias 12%). Displacement of electrode catheters after transvenous cardioversion was uncommon (3%). We conclude that transvenous cardioversion has limited efficacy for termination of VT in unselected patients. transvenous cardioversion with two different incremental energy protocols in unselected patients with recurrent and sustained VT. MethodsPatients. All patients entering this study satisfied the following selection criteria: (1) Patients had recurrent sustained VT and were undergoing clinically indicated electrophysiologic procedures. For this study, "recurrent" was defined as three or more spontaneous episodes and "sustained" as VT of greater than 30 sec duration or requiring earlier electrical or pharmacologic termination for hemodynamic compromise; (2) absence of recent (less than 30 days) myocardial infarction; (3) reproducible induction of sustained VT during electrophysiologic studies; and (4) written informed consent to undergo transvenous cardioversion.Twenty-two patients satisfied all inclusion criteria. There were 19 men and three women, mean age 64 + 9 years. All patients had organic heart disease, with a mean left ventricular ejection fraction of 31 %. Coronary artery disease was present in 18 patients and cardiomyopathy in four patients.
The following case reports represent two examples using the newly released Dilating Guide Wire. The balloon-wire system is specifically designed to be used as a steerable percutaneous transluminal coronary angioplasty (PTCA) guide wire. It can be utilized as a predilatation device in combination with a standard PTCA dilating balloon or as a free-standing dilatation catheter. As applied to the following situations, predilatation proved to be an effective time- and step-saving approach when confronting severely stenosed coronary artery lesions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.